Cevimeline vs Pilocarpine — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Cholinergic Receptor Agonist

Cevimeline

Brand: CEVIMELINE

First FDA approval: 2013-07-08

Cholinergic Receptor Agonist

Pilocarpine

Brand: Qlosi

First FDA approval: 2005-10-14

Lowest NADACAcquisition cost floor across all NDCs

$0.698Per unit

$0.349Per unit

Average NADACAcross all dosage forms and strengths

$1.49Up to $7.81

$4.66Up to $31.06

Generic manufacturersActive ANDA holders — FDA Orange Book

88 total ANDAs filed

922 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$30.3MFull year

$32.9MFull year

Part D claims (CY24)Total fills, all strengths

175K56K beneficiaries

490K176K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$173Per claim, all NDCs

$67Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

3Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

DiscontinuedSee drug profile

Generic availableFDA Orange Book

Yes8 manufacturers

Yes9 manufacturers